Acceleron Pharma (NASDAQ:XLRN) reported earnings of ($0.63) per share beating Walls Streets expectations.

ME Staff
-
0

Acceleron Pharma (NASDAQ:XLRN) reported Q2 2018 earnings this Afternoon, coming in at ($0.63) per share, beating Wall Street’s estimates of ($0.65) per Share. Revenue for the quarter came in at $3.69 million beating analyst estimates of $3.37 million

Recent Insider Trading for Acceleron Pharma (NASDAQ:XLRN)

  • On 6/29/2018 Kevin F Mclaughlin, CFO, sold 25,000 with an average share price of $48.00 per share and the total transaction amounting to $1,200,000.00.
  • On 4/3/2018 John D Quisel, SVP, sold 1,204 with an average share price of $38.40 per share and the total transaction amounting to $46,233.60.
  • On 4/3/2018 Kevin F Mclaughlin, CFO, sold 4,000 with an average share price of $38.45 per share and the total transaction amounting to $153,800.00.
  • On 4/3/2018 Matthew L Sherman, EVP, sold 4,600 with an average share price of $38.43 per share and the total transaction amounting to $176,778.00.
  • On 3/6/2018 Richard F Pops, Director, sold 37,500 with an average share price of $41.42 per share and the total transaction amounting to $1,553,250.00.
  • On 1/12/2018 Christopher Rovaldi, SVP, sold 11,000 with an average share price of $45.00 per share and the total transaction amounting to $495,000.00.



    About Company
    Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

    Recent Analyst Rating for Acceleron Pharma (NASDAQ:XLRN)



      Recent Trading for Acceleron Pharma (NASDAQ:XLRN)
      Shares of Acceleron Pharma closed the previous trading session at with 43.21 shares trading hands.